These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15621681)

  • 1. A new bifunctional chelating agent conjugated with monoclonal antibody and labelled with technetium-99m for targeted scintigraphy: 6-(4-isothiocyanatobenzyl)-5,7-dioxo-1,11-(carboxymethyl)-1,4,8,11-tetraazacyclotridecane.
    Mishra AK; Panwar P; Hosono M; Chuttani K; Mishra P; Sharma RK; Chatal JF
    J Drug Target; 2004; 12(9-10):559-67. PubMed ID: 15621681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
    Mishra G; Panwar P; Mishra AK
    Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunoscintigraphy using technetium-99m-labeled parental mouse and mouse-human chimeric antibodies to carcinoembryonic antigen in athymic nude mice bearing tumor.
    Karube Y; Katsuno K; Takata J; Matsunaga K; Haruno M; Kuroki M; Arakawa F; Matsuoka Y; Kanda H
    Nucl Med Biol; 1996 Aug; 23(6):753-9. PubMed ID: 8940717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
    Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
    Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.
    Stalteri MA; Mather SJ
    Eur J Nucl Med; 1996 Feb; 23(2):178-87. PubMed ID: 8925853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and preclinical investigation of
    Shah SQ; Gul-E-Raana
    Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (99m)Tc human IgG radiolabelled by HYNIC. Biodistribution and scintigraphy of experimentally induced inflammatory lesions in animal model.
    Karczmarczyk U; Markiewicz A; Mikołajczak R; Lisiak E; Bilski M; Pietrzykowski J; Michalik J
    Nucl Med Rev Cent East Eur; 2004; 7(2):107-12. PubMed ID: 15968595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies.
    Ram S; Buchsbaum DJ
    Cancer; 1994 Feb; 73(3 Suppl):769-73. PubMed ID: 8306258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
    Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor.
    Takasu S; Takahashi T; Okamoto S; Oriuchi N; Nakayashiki N; Okamoto K; Muramatsu H; Hayashi T; Nakahara N; Mizuno M; Wakabayashi T; Higuchi T; Endo K; Kozaki K; Miyaishi O; Saga S; Ueda R; Yoshida J; Yoshikawa K
    J Neurooncol; 2003 Jul; 63(3):247-56. PubMed ID: 12892230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunoscintigraphy of colorectal cancer with technetium-99m-labeled murine anti-carcinoembryonic antigen monoclonal antibody in athymic nude mice.
    Watanabe N; Oriuchi N; Sugiyama S; Kuroki M; Matsuoka Y
    Ann Nucl Med; 1994 Feb; 8(1):23-30. PubMed ID: 8204394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmuno targetting (99m)technetium labeled anti-epidermal growth factor receptor monoclonal antibodies in experimental tumor models.
    Meenakshi A; Ganesh V; Suresh Kumar R; Siva Kumar N
    Q J Nucl Med; 2003 Jun; 47(2):139-44. PubMed ID: 12865874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of a new bifunctional chelating agent for the preparation of radioimmunoconjugates.
    Somayaji VV; Guay V; Peng Z; Sykes TR; Noujaim AA
    Q J Nucl Med; 1995 Dec; 39(4):300-10. PubMed ID: 8624793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
    Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):722-733. PubMed ID: 17146656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent.
    Fritzberg AR; Abrams PG; Beaumier PL; Kasina S; Morgan AC; Rao TN; Reno JM; Sanderson JA; Srinivasan A; Wilbur DS
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):4025-9. PubMed ID: 3375252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and Evaluation of (99m)Tc-Epidermal Growth Factor Receptor (EGFR)-Peptide Nucleic Acid for Visualization of EGFR Messenger RNA Expression in Malignant Tumors.
    Zhao X; Wang N; Ren X; Zhang J; Wang J; Han J; Jia L; Liu Y; Zhang Z
    J Nucl Med; 2014 Jun; 55(6):1008-16. PubMed ID: 24744447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours.
    Abiraj K; Mansi R; Tamma ML; Forrer F; Cescato R; Reubi JC; Akyel KG; Maecke HR
    Chemistry; 2010 Feb; 16(7):2115-24. PubMed ID: 20066690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA.
    Hertel A; Baum RP; Lorenz M; Baew-Christow T; Encke A; Hör G
    Br J Cancer Suppl; 1990 Jul; 10():34-6. PubMed ID: 2166552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with 111In-anti-CEA monoclonal antibody.
    Faivre-Chauvet A; Mease RC; Chetanneau A; Bardiès M; Sai-Maurel C; Meinken GE; Srivastava SC; Chatal JF; Gestin JF
    Nucl Med Commun; 1996 Sep; 17(9):781-9. PubMed ID: 8895905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.